Liver Diseases  >>  ascrinvacumab (GT90001)  >>  Phase 2
Welcome,         Profile    Billing    Logout  

1 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
ascrinvacumab (GT90001) / Kintor Pharma
NCT01911273 / 2013-001426-26: A Study To Evaluate The Efficacy And Safety of The Investigational Drug PF-03446962 (A Monoclonal Antibody With Antiangiogenic Features) In Combination With Best Supportive Care Versus Placebo Plus Best Supportive Care In Patients Affected By Recurrent Liver Cancer

Terminated
2
3
Japan, US
PF-03446962, Best Supportive Care, Placebo
Pfizer
Carcinoma, Hepatocellular
07/14
07/14

Download Options